Official Journal of the Society

Nucleic Acid Therapeutics is the Official Journal of the OTS. It is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines nucleic acids as therapeutic agents or modifying nucleic acids for therapeutic purposes including: single and double stranded oligonucleotides, oligonucleotide chemistry, gene modification, aptamers, RNA nanoparticles, and ribozymes.

It welcomes research papers and reviews, but also commentaries on recent oligonucleotide therapeutic developments. OTS members can access the Journal via the member website, and we encourage members to submit their work to the Journal and to recommend the Journal to their library or institution to facilitate collaboration with colleagues. We highly value input from our members and invite you to reach out to us at We also welcome suggestions for special issues focusing on a specific approach, disease field or development stage.

The Journal is led by Co-Editors-in-Chief Bruce A. Sullenger, PhD and Annemieke Aartsma-Rus, PhD, Executive Editor Graham Parker, PhD, Senior Editors David Corey, PhD, Mark Kay, MD, PhD and Brett Monia, PhD, European Editor Jens Kurreck, PhD and Asian Editor Dong-ki Lee, PhD and other leading investigators. View the entire editorial board.

Read a free issue of Nucleic Acid Therapeutics online.

  • RFS Awards in Science Winner

Mary Ann Liebert, Inc., in partnership with the Rosalind Franklin Society launched a prestigious annual award to recognize outstanding published peer-reviewed research by women and underrepresented minorities in science in each of the publisher’s peer-reviewed journals. The RFS Awards in Science for Nucleic Acid Therapeutics has selected Laura Sepp-Lorenzino, PhD because she has served as a great role model for women and minorities on the pharma/biotech area in the field, and has served Nucleic Acid Therapeutics as a reviewer, author, and editorial board member.

View RFS Awards in Science Book

  • New Impact Factor: 5.5

    Nucleic Acid Therapeutics announces a new impact factor of 5.486*, a 10% increase over last year! The Journal remains a critical resource for cutting-edge peer-reviewed research on using nucleic acids and related compounds to alter gene expression for therapeutic purposes.

    With an average time to first decision of 17 days, open access publishing options, and accessibility in 170 countries worldwide, publishing with Nucleic Acid Therapeutics ensures your manuscript has the impact and receives the attention it deserves.

    2020 Journal Citation Reports (Clarivate, 2021)

    CiteScore™: 7.5

Paper Submissions

Submit your paper online today! Accepted papers are published online ahead of The Journal features rapid peer review and publication online within 6 weeks of acceptance, and offers Open Access options (with discounts for members). Detailed information and instructions for authors is available online.

Subscription to Nucleic Acid Therapeutics

Nucleic Acid Therapeutics (formerly Oligonucleotides) is the official journal of the OTS. OTS members are entitled to the valuable benefit of a deeply discounted subscription to Nucleic Acid Therapeutics, including access to the full, searchable journal archive.

Become a member of the OTS today to start your discounted subscription to Nucleic Acid Therapeutics!

Already a member?  Login to the online member portal to access your discounted subscription offer to Nucleic Acid Therapeutics.